PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Katherine L Nelson,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Tammeka Evans Cooper,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Yolanda Lawson,"MadeWell OBGYN, Dallas, Texas, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Satish Mocherla,"Legacy Community Health Services, Houston, Texas, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Alftan Dyson,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Denise Sutherland-Philips,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Heidi Swygard,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Lisa Petty,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Peter Jeffery,"GSK, London, UK.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Kenneth Sutton,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Courtney Peasant Bonner,"RTI International, Research Triangle Park, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Sara M Andrews,"RTI International, Research Triangle Park, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Samantha Chang,"RTI International, Research Triangle Park, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Piotr Budnik,"ViiV Healthcare, London, UK.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Kimberly Smith,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Annemiek de Ruiter,"ViiV Healthcare, London, UK.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Maggie Czarnogorski,"ViiV Healthcare, Durham, North Carolina, USA.",
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,Nanlesta Pilgrim,"ViiV Healthcare, Durham, North Carolina, USA.",
40594462,A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting.,2025,Nur Diana Anuar,"Sengenics Corporation, Level M, Plaza Zurich, Damansara Heights, 50490, Kuala Lumpur, Malaysia.",
40594462,A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting.,2025,Ti-Myen Tan,"Sengenics Corporation, Level M, Plaza Zurich, Damansara Heights, 50490, Kuala Lumpur, Malaysia.",
40555671,Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions.,2025,Yoshio Hirota,"Clinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co., LTA), Fukuoka, Japan.",
40519918,Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain.,2025,Luis Sarabia de Ardanaz,"Universidad de Granada, Departamento de Medicina Preventiva y Salud Pública, Granada, Spain.",
40519918,Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain.,2025,Alba Leyva,"Vircell, S.L., Granada, Spain.",
40519918,Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain.,2025,Pilar Requena,"Universidad de Granada, Departamento de Medicina Preventiva y Salud Pública, Granada, Spain.",
40489510,"Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study.",2025,Erlina Burhan,"Indonesia Society of Respirology, Jakarta, Indonesia.",
40489510,"Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study.",2025,Sabarinah Prasetyo,"Faculty of Public Health Universitas Indonesia, West Java, Indonesia.",
40489510,"Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study.",2025,Dwi Gayatri,"Faculty of Public Health Universitas Indonesia, West Java, Indonesia.",
40489510,"Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study.",2025,Iwan Ariawan,"Faculty of Public Health Universitas Indonesia, West Java, Indonesia.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Eliza Mari Kwesi-Maliepaard,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Yakubu Alhassan,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Emmanuel K Quaye,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Vera M Kotey,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Aisha M Mohammed,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Seth Agyemang,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Adelaide K Sromani,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Stephanie Darko,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Erica Buadii,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Randy Tackie,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Harry Akligoh,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Barikisu Ibrahim,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,David Hutchful,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Lily Paemka,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Emmanuella Amoako,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Joyce M Ngoi,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Aida Manu,"Yemaachi Biotech, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Abdul Razak Quao,"Adabraka Polyclinic, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Akosua Ayisi,"Ghana Health Service, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Kwame Amponsa-Achiano,"Ghana Health Service, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Franklin Asiedu Bekoe,"Ghana Health Service, Accra, Ghana.",
40437463,Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.,2025,Yaw Bediako,"Yemaachi Biotech, Accra, Ghana. yaw@yemaachi.com.",yaw@yemaachi.com
40436912,Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens.,2025,Yoshio Hirota,"Clinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co. LTA), Fukuoka, Japan.",
40436912,Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens.,2025,Tomomi Tsuru,"PS Clinic, SOUSEIKAI Medical Group (Medical Co. LTA), Fukuoka, Japan. tomomi-tsuru@lta-med.com.",tomomi-tsuru@lta-med.com
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Fatima de Cássia Evangelista de Oliveira,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Ana Carolina Matias Dinelly Pinto,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Maria Francilene Souza Silva,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Max Moreira Lizano Garcia,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Maria da Conceição Rodrigues Fernandes,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Gabriela Alexandria Damasceno,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Amanda Campelo Lima de Melo,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Tamires Cardoso Matsui,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Tamiris de Fátima Goebel de Souza,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Caroline Passaes,"Pasteur-Fiocruz Center on Immunology and Immunotherapy, Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Fernanda Montenegro de Carvalho Araújo,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Luiz Odorico Monteiro de Andrade,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40430765,The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil.,2025,Marcela Helena Gambim Fonseca,"Unidade de Apoio ao Diagnóstico da COVID-19, Fundação Oswaldo Cruz (Fiocruz), Eusébio 61773-270, Ceará, Brazil.",
40406109,Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster.,2025,Roberto Stefan de Almeida Ribeiro,"Laboratory of Immunopathology (LIP), Discipline of General Pathology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.",
40406109,Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster.,2025,Vinicius da Cunha Lisboa,"Laboratory of Immunopathology (LIP), Discipline of General Pathology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.",
40406109,Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster.,2025,Samara Galdino de Azevedo,"Laboratory of Immunopathology (LIP), Discipline of General Pathology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.",
40406109,Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster.,2025,Luciana Silva Rodrigues,"Laboratory of Immunopathology (LIP), Discipline of General Pathology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Kyle Fahrbach,"Evidence Synthesis, Evidera Inc., Wilmington, NC, USA.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Allie Cichewicz,"Evidence Synthesis, Evidera Inc., Wilmington, NC, USA.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Haitao Chu,"Statistics, Pfizer Inc., New York, NY, USA.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Manuela Di Fusco,"Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Heather Burnett,"Evidence Synthesis, Evidera Inc., Wilmington, NC, USA.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Hannah R Volkman,"Medical Affairs, Pfizer Inc., New York, NY, USA.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Morodoluwa Akin-Fajiye,"Evidence Synthesis, Evidera Inc., Wilmington, NC, USA.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Carlos Fernando Mendoza,"Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA.",
40357526,Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.,2025,Joseph C Cappelleri,"Statistics, Pfizer Inc., New York, NY, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Patricia C Lloyd,"US Food and Drug Administration, Silver Spring, Maryland, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Elizabeth R Smith,"Acumen LLC, Burlingame, California, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Joann F Gruber,"US Food and Drug Administration, Silver Spring, Maryland, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Michelle Ondari,"Acumen LLC, Burlingame, California, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Hui Lee Wong,"US Food and Drug Administration, Silver Spring, Maryland, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Mao Hu,"Acumen LLC, Burlingame, California, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Tainya C Clarke,"US Food and Drug Administration, Silver Spring, Maryland, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Rowan McEvoy,"Acumen LLC, Burlingame, California, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Kandace L Amend,"Optum Epidemiology, Boston, Massachusetts, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Daniel C Beachler,"Carelon Research, Wilmington, Delaware, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Cheryl N McMahill-Walraven,"CVS Health, Blue Bell, Pennsylvania, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,John D Seeger,"Optum Epidemiology, Boston, Massachusetts, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Alex Secora,"IQVIA, Falls Church, Virginia, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Djeneba Audrey Djibo,"CVS Health, Blue Bell, Pennsylvania, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Jennifer Song,"Optum Epidemiology, Boston, Massachusetts, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Nandini Selvam,"IQVIA, Falls Church, Virginia, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Jonathan P DeShazo,"CVS Health, Blue Bell, Pennsylvania, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Robin Clifford,"Optum Epidemiology, Boston, Massachusetts, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Eugenio Abente,"CVS Health, Blue Bell, Pennsylvania, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Yoganand Chillarige,"Acumen LLC, Burlingame, California, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Richard A Forshee,"US Food and Drug Administration, Silver Spring, Maryland, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Steven A Anderson,"US Food and Drug Administration, Silver Spring, Maryland, USA.",
40328431,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States.,2025,Azadeh Shoaibi,"US Food and Drug Administration, Silver Spring, Maryland, USA.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,J Bradley Layton,"RTI Health Solutions, Research Triangle Park, North Carolina, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Patricia C Lloyd,"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Lauren S Peetluk,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Yixin Jiao,"Acumen LLC, Burlingame, California, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Djeneba Audrey Djibo,"Safety Surveillance & Collaboration, CVS Health, Blue Bell, Pennsylvania, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Joann F Gruber,"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Jie Deng,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Christine Bui,"RTI Health Solutions, Research Triangle Park, North Carolina, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,An-Chi Lo,"Acumen LLC, Burlingame, California, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Rachel P Ogilvie,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Ron Parambi,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Michael Miller,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Jennifer Song,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Lisa B Weatherby,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Sylvia Cho,"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Hui Lee Wong,"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Tainya C Clarke,"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Jessica Rose Hervol,"Acumen LLC, Burlingame, California, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Dóra Illei,"RTI International, Washington, District of Columbia, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Elizabeth J Bell,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Grace Wenya Yang,"OptumServe, Falls Church, Virginia, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,John D Seeger,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Michael Wernecke,"Acumen LLC, Burlingame, California, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Morgan M Richey,"RTI Health Solutions, Research Triangle Park, North Carolina, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Richard A Forshee,"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Steven A Anderson,"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Yoganand Chillarige,"Acumen LLC, Burlingame, California, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Cheryl N McMahill-Walraven,"Safety Surveillance & Collaboration, CVS Health, Blue Bell, Pennsylvania, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Kandace L Amend,"Optum Epidemiology, Boston, Massachusetts, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Mary S Anthony,"RTI Health Solutions, Research Triangle Park, North Carolina, United States of America.",
40327641,Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.,2025,Azadeh Shoaibi,"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.",
40304691,"Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.",2025,José Molto,"CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.",
40304691,"Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.",2025,Laia Bernad,"Irsicaixa, Badalona, Spain.",
40304691,"Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.",2025,Raúl Pérez-Caballero,"Irsicaixa, Badalona, Spain.",
40304691,"Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.",2025,Montserrat Plana,"CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.",
40304691,"Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.",2025,Júlia G Prado,"CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.",
40304691,"Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.",2025,Álex Soriano,"CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.",
40301395,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.,2025,Haley J Appaneal,"Infectious Diseases Research Program, Providence Veterans Affairs Healthcare System, Providence, RI, US.",
40301395,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.,2025,Vrishali V Lopes,"Infectious Diseases Research Program, Providence Veterans Affairs Healthcare System, Providence, RI, US.",
40301395,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.,2025,Laura Puzniak,"Pfizer Inc., New York, NY, US.",
40301395,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.,2025,Evan J Zasowski,"Pfizer Inc., New York, NY, US.",
40301395,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.,2025,Luis Jodar,"Pfizer Inc., New York, NY, US.",
40301395,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.,2025,John M McLaughlin,"Pfizer Inc., New York, NY, US.",
40301395,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.,2025,Aisling R Caffrey,"Infectious Diseases Research Program, Providence Veterans Affairs Healthcare System, Providence, RI, US. Aisling_Caffrey@uri.edu.",Aisling_Caffrey@uri.edu
40300604,Macrophages direct location-dependent recall of B cell memory to vaccination.,2025,Mitchell Starr,"St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.",
40281454,Long-term immune response after SARS-CoV2 vaccination in solid organ transplant recipients.,2025,Dino Gibertoni,"Epidemiology and Statistics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.",
40281454,Long-term immune response after SARS-CoV2 vaccination in solid organ transplant recipients.,2025,Maria Cristina Morelli,"Internal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.",
40281454,Long-term immune response after SARS-CoV2 vaccination in solid organ transplant recipients.,2025,Elena Salvaterra,"Division of Interventional Pulmonology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.",
40281454,Long-term immune response after SARS-CoV2 vaccination in solid organ transplant recipients.,2025,Luciano Potena,"Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.",
40268657,mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation.,2025,Valerie Duval,"Combined Therapeutics Incorporated, Boston, MA 02135, USA.",
40268657,mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation.,2025,Romain Micol,"Combined Therapeutics Incorporated, Boston, MA 02135, USA.",
40240603,Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines.,2025,Paweł Turowski,"ExploRNA Therapeutics, Warsaw, Poland.",
40222985,Genome-wide association study of common side effects following COVID-19 booster vaccination in a cohort of corporate employees in Japan.,2025,Taihei Yamaguchi,"Life Science Business Office, Corporate Technology Planning Division, Toshiba Corporation, Tokyo, Japan.",
40222985,Genome-wide association study of common side effects following COVID-19 booster vaccination in a cohort of corporate employees in Japan.,2025,Maiko Yagi,"Life Science Business Office, Corporate Technology Planning Division, Toshiba Corporation, Tokyo, Japan.",
40222985,Genome-wide association study of common side effects following COVID-19 booster vaccination in a cohort of corporate employees in Japan.,2025,Masashi Ebisawa,"Life Science Business Office, Corporate Technology Planning Division, Toshiba Corporation, Tokyo, Japan.",
40222985,Genome-wide association study of common side effects following COVID-19 booster vaccination in a cohort of corporate employees in Japan.,2025,Wataru Sugiura,"Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.",
40213554,Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar.,2025,Ahmed Zaqout,"Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar.",
40213554,Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar.,2025,Abdullah Aldushain,"Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar.",
40213554,Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar.,2025,Mohammed Abukhattab,"Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar.",
40213554,Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar.,2025,Muna A Almaslamani,"Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar.",
40213554,Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar.,2025,Ali S Omrani,"Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar.",
40189198,Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.,2025,Muhammad Azeem,"Dipartimento di Medicina di Precisione in Area Medica, Chirurgica e Critica (Me.Pre.C.C.), Università degli Studi di Palermo, Via Liborio Giuffre, 590127 Palermo, Italy.",
40189198,Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.,2025,Patrizia Cancemi,"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.",
40189198,Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.,2025,Farwa Mukhtar,"Dipartimento di Medicina e Scienze della Salute ""V. Tiberio"", Università degli Studi del Molise, Campobasso, Italy.",
40189198,Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.,2025,Sefora Marino,"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.",
40189198,Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.,2025,Emanuela Peri,"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.",
40189198,Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.,2025,Giulia Di Prima,"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.",
40189198,Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.,2025,Viviana De Caro,"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Bianca da Silva Almeida,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Guilherme Antonio de Souza-Silva,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Rodolfo Ferreira Marques,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Gustavo Henrique Corrêa Soares,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Robert Andreata-Santos,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Mariângela de Oliveira Silva,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Marcio Yamamoto,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Luís Carlos de Souza Ferreira,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Daniela Santoro Rosa,"Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil; Instituto de Investigação em Imunologia-Instituto Nacional de Ciências e Tecnologia (iii-INCT), São Paulo 05403-000, Brazil.",
40185297,"Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.",2025,Silvia Beatriz Boscardin,"Instituto Ciências Biomédicas da Universidade de São Paulo, ICB-USP, São Paulo 05508-000, Brazil; Instituto de Investigação em Imunologia-Instituto Nacional de Ciências e Tecnologia (iii-INCT), São Paulo 05403-000, Brazil. Electronic address: sbboscardin@usp.br.",sbboscardin@usp.br
40175001,"A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.",2025,Lelia Duley,"CLL Support Association, London, UK.",
40170841,T and B cell responses in different immunization scenarios for COVID-19: a narrative review.,2025,Irini Zografaki,"mRNA & Antivirals Medical & Scientific Affairs International Developed Markets, Pfizer, Athens, Greece.",
40148999,Seven-month persistence of COVID-19 vaccine-induced lymphadenopathy: a case report.,2025,Hemi Dua,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.",
40136202,An institutional COVID-19 initiative: creation of a biobank and serological data analysis in pre- and post-vaccination cohorts.,2025,Lorena O Fernandes-Siqueira,"Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil.",
40136202,An institutional COVID-19 initiative: creation of a biobank and serological data analysis in pre- and post-vaccination cohorts.,2025,Raphael R A Melo,"Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil.",
40136202,An institutional COVID-19 initiative: creation of a biobank and serological data analysis in pre- and post-vaccination cohorts.,2025,Luciana S Wermelinger,"Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Faculdade de Farmácia, Avenida Carlos Chagas Filho, 373, Bloco A, Cidade Universitária, Ilha do Fundão, 21941-170 Rio de Janeiro, RJ, Brazil.",
40136202,An institutional COVID-19 initiative: creation of a biobank and serological data analysis in pre- and post-vaccination cohorts.,2025,Fabio C L Almeida,"Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil.",
40136202,An institutional COVID-19 initiative: creation of a biobank and serological data analysis in pre- and post-vaccination cohorts.,2025,Didier Salmon,"Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil.",
40136202,An institutional COVID-19 initiative: creation of a biobank and serological data analysis in pre- and post-vaccination cohorts.,2025,Gustavo C Ferreira,"Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil.",
40136202,An institutional COVID-19 initiative: creation of a biobank and serological data analysis in pre- and post-vaccination cohorts.,2025,Andrea T DA Poian,"Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil.",
40114918,Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.,2025,Vitor Gabriel Lopes da Silva,"Departamento de Pediatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.",
40114918,Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.,2025,Gabriela Justamante Händel Schmitz,"Departamento de Clínica Médica, Universidade de São Paulo, São Paulo, SP, Brazil.",
40114918,Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.,2025,Júlia Barbate,"Departamento de Pediatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.",
40114918,Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.,2025,Maria Izabel de Haro Azinar,"Departamento de Pediatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.",
40114918,Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.,2025,Carolina Sanchez Aranda,"Departamento de Pediatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.",
40114918,Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.,2025,Maria Isabel de Moraes-Pinto,"Departamento de Pediatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.",
40112019,"Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.",2025,Maryo Baakliny,"Université Paris-Est Créteil Val de Marne, Créteil, France.",
40112019,"Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.",2025,Nada Ghosn,"Epidemiological Surveillance Unit, Ministry of Public Health, Beirut, Lebanon.",
40112019,"Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.",2025,Patrick Maison,"Université Paris-Est Créteil Val de Marne, Créteil, France.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Wilhelmine Meeraus,"Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK. Electronic address: wilhelmine.meeraus@astrazeneca.com.",wilhelmine.meeraus@astrazeneca.com
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Abigail Postema,"Formerly Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Christen M Gray,"Real World Data Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Andrew Lee,"Medical and Payor Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Andre Santa Maria,"Early Phase Clinical Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Bárbara Emoingt Furtado,"Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Eduardo Conde-Sousa,"Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Mario Ouwens,"Medical and Payor Statistics, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Douglas Andreas Valverde,"Techtrials Healthcare Data Science, São Paulo, Brazil.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Claudia Corte,"Formerly Evidence Generation, AstraZeneca, São Paulo, Brazil.",
40068393,Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.,2025,Sylvia Taylor,"Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Xuan Wang,"ICON plc, Stockholm, Sweden.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Ankit Pahwa,"ICON plc, Bengaluru, India.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Mary T Bausch-Jurken,"Moderna, Inc., Cambridge, MA, USA.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Anushri Chitkara,"ICON plc, Bengaluru, India.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Pawana Sharma,"ICON plc, London, UK.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Mia Malmenäs,"ICON plc, Stockholm, Sweden.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Sonam Vats,"ICON plc, Bengaluru, India.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Michael Gordon Whitfield,"ICON plc, London, UK.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Kira Zhi Hua Lai,"ICON plc, Toronto, ON, Canada.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Priyadarsini Dasari,"ICON plc, Blue Bell, PA, USA.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Ritu Gupta,"ICON plc, Bengaluru, India.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Maria Nassim,"ICON plc, Langen, Germany.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Nicolas Van de Velde,"Moderna, Inc., Cambridge, MA, USA.",
40063213,Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.,2025,Ekkehard Beck,"Moderna, Inc., Cambridge, MA, USA. Ekkehard.beck@modernatx.com.",Ekkehard.beck@modernatx.com
40062079,Cardiac Complications Associated With COVID-19 Vaccination: A Systematic Review of Cohort Studies.,2025,Indraneel Banerjee,"Urology, Penn Highlands Healthcare, Pennsylvania, USA.",
40043710,Germline variants and mosaic chromosomal alterations affect COVID-19 vaccine immunogenicity.,2025,Shinichi Higashiue,"Tokushukai Group, Tokyo, Japan.",
40043710,Germline variants and mosaic chromosomal alterations affect COVID-19 vaccine immunogenicity.,2025,Shuzo Kobayashi,"Tokushukai Group, Tokyo, Japan.",
40034392,Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children.,2025,Constanza Russo,"Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina.",
40034392,Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children.,2025,Adrián Otero,"Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina.",
40034392,Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children.,2025,Vanesa Seery,"Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina.",
40034392,Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children.,2025,Norberto De Carli,"Servicio de Pediatria, Clínica del Niño de Quilmes, Buenos Aires, Argentina.",
40034392,Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children.,2025,Luisa Aedo Portela,"Servicio de Pediatria, Clínica del Niño de Quilmes, Buenos Aires, Argentina.",
40034392,Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children.,2025,Misael Salcedo Pereira,"Servicio de Pediatria, Clínica del Niño de Quilmes, Buenos Aires, Argentina.",
40034392,Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children.,2025,Jorge Geffner,"Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina.",
40034392,Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children.,2025,Lourdes Arruvito,"Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina.",
40033413,Post coronavirus-disease-vaccination immune reconstitution inflammatory syndrome in tuberculosis treatment: a case report.,2025,Alok Pant,", Shreveport, LA, 71103, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Oyeniyi Diya,"Vaccine Research and Development, Pfizer Ltd, Marlow, UK. Electronic address: Oyeniyi.Diya@pfizer.com.",Oyeniyi.Diya@pfizer.com
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Juleen Gayed,"Vaccine Research and Development, Pfizer Ltd, Marlow, UK.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Federico Mensa,"BioNTech, Mainz, Germany.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Mark Cutler,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Todd Belanger,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,David Cooper,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Xia Xu,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Kenneth Koury,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Özlem Türeci,"BioNTech, Mainz, Germany.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Uǧur Şahin,"BioNTech, Mainz, Germany.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Kena A Swanson,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Kayvon Modjarrad,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Annaliesa S Anderson,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Alejandra Gurtman,"Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.",
39999538,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.,2025,Nicholas Kitchin,"Vaccine Research and Development, Pfizer Ltd, Marlow, UK.",
39991976,"The Effect of HLA Polymorphism on Immune Response to SARS-CoV-2 Vaccination Within an Infection-Naïve, Vulnerable Population With End-Stage Renal Disease.",2025,Eva Santos,"NHS North West London Pathology, London, UK.",
39991976,"The Effect of HLA Polymorphism on Immune Response to SARS-CoV-2 Vaccination Within an Infection-Naïve, Vulnerable Population With End-Stage Renal Disease.",2025,Arthi Anand,"NHS North West London Pathology, London, UK.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Kathleen M Andersen,"Pfizer Inc., New York, New York, United States. Electronic address: Kathleen.andersen@pfizer.com.",Kathleen.andersen@pfizer.com
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Kristen E Allen,"Pfizer Inc., New York, New York, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Rajeev M Nepal,"Pfizer Inc., New York, New York, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Jazmine S Mateus,"Genesis Research Group, Hoboken, New Jersey, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Tiange Yu,"Genesis Research Group, Hoboken, New Jersey, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Anan Zhou,"Genesis Research Group, Hoboken, New Jersey, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Thomas M Porter,"Pfizer Inc., New York, New York, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Santiago M C Lopez,"Pfizer Inc., New York, New York, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Laura Puzniak,"Pfizer Inc., New York, New York, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,John M McLaughlin,"Pfizer Inc., New York, New York, United States.",
39987879,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.,2025,Leah J McGrath,"Pfizer Inc., New York, New York, United States.",
39977462,Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes.,2025,Thevesh Thevananthan,"Disease Control Division, Ministry of Health Malaysia, Putrajaya, Malaysia.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Ekkehard Beck,"Moderna, Inc, Cambridge, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Mihaela Georgieva,"Moderna, Inc, Cambridge, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Wei-Jhih Wang,"Moderna, Inc, Cambridge, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Andres Gomez-Lievano,"Analysis Group, Inc, Boston, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Hongjue Wang,"Analysis Group, Inc, London, UK.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Yipeng Gao,"Analysis Group, Inc, Boston, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Hagit Kopel,"Moderna, Inc, Cambridge, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Mary Bausch-Jurken,"Moderna, Inc, Cambridge, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Oscar Patterson-Lomba,"Analysis Group, Inc, Boston, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Fan Mu,"Analysis Group, Inc, Boston, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Eric Wu,"Analysis Group, Inc, Boston, MA, USA.",
39973309,Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.,2025,Nicolas Van de Velde,"Moderna, Inc, Cambridge, MA, USA.",
39953414,Neutralizing and binding antibody dynamics following primary and booster COVID-19 vaccination among healthcare workers.,2025,Ahmet F Süner,"Çaycuma District Health Directorate, Zonguldak, Turkey.",
39931577,Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.,2024,Thomas E Hickey,"Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.",
39931577,Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.,2024,Uma Mudunuri,"Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.",
39931577,Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.,2024,Heidi A Hempel,"Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.",
39931577,Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.,2024,Troy J Kemp,"Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.",
39931577,Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.,2024,Nancy V Roche,"Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.",
39931577,Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.,2024,Keyur Talsania,"Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.",
39931577,Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.,2024,Ligia A Pinto,"Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.",
39928242,Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands.,2025,Florian Zeevat,"Health-Ecore, Utrechtseweg 60, 3704 HE, Zeist, The Netherlands. florianzeevat@health-ecore.com.",florianzeevat@health-ecore.com
39928242,Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands.,2025,Simon van der Pol,"Health-Ecore, Utrechtseweg 60, 3704 HE, Zeist, The Netherlands.",
39928242,Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands.,2025,Tjalke Westra,"Moderna Netherlands, Amsterdam, The Netherlands.",
39928242,Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands.,2025,Ekkehard Beck,"Moderna Inc, Cambridge, MA, USA.",
39928242,Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands.,2025,Maarten J Postma,"Health-Ecore, Utrechtseweg 60, 3704 HE, Zeist, The Netherlands.",
39928242,Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands.,2025,Cornelis Boersma,"Health-Ecore, Utrechtseweg 60, 3704 HE, Zeist, The Netherlands.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Maaweya Awadalla,"Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Halah Z AlRawi,"Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Rahaf A Henawi,"Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Fawziya Barnawi,"Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Haitham Alkadi,"Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Ahmed Alyami,"Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Ammar Alsughayir,"Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Alyazeed S Alsaif,"Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39911379,Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.,2025,Bandar Alosaimi,"Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.",
39902042,Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.,2024,Sylvain Lamure,"Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, France.",
39902042,Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.,2024,Houria Hendel Chavez,"Laboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, France.",
39902042,Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.,2024,Marie-Ghislaine de Goër de Herve,"Laboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, France.",
39902042,Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.,2024,Luc-Matthieu Fornecker,"Service d'Hématologie, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.",
39902042,Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.,2024,Angela Jackson,"Université Paris-Saclay, Université de Versailles - Saint-Quentin-en-Yvelines (UVSQ), Inserm, Équipe ""Exposome et Hérédité"", Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France.",
39902042,Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.,2024,Rémy Duléry,"Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, Assistance Publique - Hôpitaux de Paris, Sorbonne Université, Inserm UMRs 938, Paris, France.",
39902042,Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.,2024,Yassine Taoufik,"Laboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, France.",
39894227,BNT162b2 COVID-19 vaccination elicits the expansion of CD16,2025,Massimo Vitale,"Unit of Experimental Pathology and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy.",
39879847,"Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.",2025,Susumu Kusunoki,"Japan Community Health Care Organization Headquarters, 3-22-12, Takanawa, Minato-ku, Tokyo 108-0074, Japan. Electronic address: kusunoki@med.kindai.ac.jp.",kusunoki@med.kindai.ac.jp
39879847,"Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.",2025,Yoshihiro Kaneko,"Japan Organization of Occupational Health and Safety Headquarters, 1-1, Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki-shi, Kanagawa 211-0021, Japan. Electronic address: yoshihiro-kaneko@honbu.johas.go.jp.",yoshihiro-kaneko@honbu.johas.go.jp
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Vanessa Infante,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Maria Isabel de Moraes Pinto,"Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Pediatria, Disciplina de Alergia, Imunologia Clínica e Reumatologia, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Liliane Saraiva de Mello,"Universidade de São Paulo, Faculdade de Medicina, Instituto do Coração, Serviço de Pneumologia, Unidade de Transplante de Pulmão, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Vitor Gabriel Lopes da Silva,"Universidade Federal de São Paulo, Disciplina de Infectologia Pediátrica, Laboratório de Pesquisas, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Lucas Ragiotto,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Pedro Henrique Theotonio de Mesquita Pacheco,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Patricia Emilia Braga,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Ana Paula Loch,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Alexander Roberto Precioso,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,João Ítalo França,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Marcos Alves de Lima,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Camila Cristina Martini Rodrigues,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Ariane Cristina Barboza Zanetti,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Bruna Ribeiro de Oliveira,"Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Pediatria, Disciplina de Alergia, Imunologia Clínica e Reumatologia, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Carolina Sanches Aranda,"Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Pediatria, Disciplina de Alergia, Imunologia Clínica e Reumatologia, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Carolinne Paioli Troli,"Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Pediatria, Disciplina de Alergia, Imunologia Clínica e Reumatologia, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Cristina M Kokron,"Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Pediatria, Disciplina de Alergia, Imunologia Clínica e Reumatologia, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Jaqueline Oliveira Santana,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Maria Teresa Terreri,"Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Pediatria, Disciplina de Alergia, Imunologia Clínica e Reumatologia, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Samia Silveira Souza Teixeira,"Instituto Butantan, Divisão de Ensaios Clínicos e Farmacovigilância, Centro de Farmacovigilância, Segurança Clínica e Gestão de Risco, São Paulo, São Paulo, Brazil.",
39841781,Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.,2025,Silvia Vidal Campos,"Universidade de São Paulo, Faculdade de Medicina, Instituto do Coração, Serviço de Pneumologia, Unidade de Transplante de Pulmão, São Paulo, São Paulo, Brazil.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Yong-Sik Bong,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,David Brown,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Ezra Chung,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Neeti Ananthaswamy,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Renxiang Chen,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Evan Lewoczko,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,William Sabbers,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Athéna C Patterson-Orazem,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Zachary Dorsey,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Yiqing Zou,"Guangzhou RNAimmune, Ltd., Guangzhou, China.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Xue Yu,"Guangzhou RNAimmune, Ltd., Guangzhou, China.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Jiening Liang,"Guangzhou RNAimmune, Ltd., Guangzhou, China.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Jiaxi He,"Guangzhou RNAimmune, Ltd., Guangzhou, China.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Steven Long,"RNAimmune, Inc., Germantown, MD, United States.",
39830514,S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.,2024,Dong Shen,"RNAimmune, Inc., Germantown, MD, United States.",
39826861,Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.,2025,Justin Green,"Vaccines and Immune Therapies Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Myriam Arévalo-Herrera,"Centro Internacional de Vacunas, Cali, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Bladimiro Rincón-Orozco,"Universidad Industrial de Santander, Escuela de Medicina, Bucaramanga, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,John Mario González-Escobar,"Universidad de los Andes, Bogotá, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Sonia Marcela Herrera-Arévalo,"Centro Internacional de Vacunas, Cali, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Elena Carrasquilla-Agudelo,"Centro Internacional de Vacunas, Cali, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Paula Andrea Serna-Ortega,"Centro Internacional de Vacunas, Cali, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Sebastián Quiceno-García,"Centro Internacional de Vacunas, Cali, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Nicolas Palacio-Muñoz,"Centro Internacional de Vacunas, Cali, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Brandon Rosero-López,"Centro Internacional de Vacunas, Cali, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Ernesto Mondol-Miranda,"Centro Internacional de Vacunas, Cali, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Ivette Freyle-Roman,"Universidad Industrial de Santander, Escuela de Medicina, Bucaramanga, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Brayan Mendoza-Landinez,"Universidad Industrial de Santander, Escuela de Medicina, Bucaramanga, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Eliana Mora-Guevara,"Universidad Industrial de Santander, Escuela de Medicina, Bucaramanga, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Juan Carlos Santos-Barbosa,"Universidad de los Andes, Bogotá, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Francisco Bohórquez-Martínez,"Universidad de los Andes, Bogotá, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Natalia Bolaños-Cristancho,"Universidad de los Andes, Bogotá, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Mónica Jiménez-Serna,"Fundación Santa Fe de Bogotá, Salud Poblacional, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,María A Nieto-Rojas,"Fundación Santa Fe de Bogotá, Salud Poblacional, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,David Suarez-Zamora,"Fundación Santa Fe de Bogotá, Salud Poblacional, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Juliana Quintero-Espinosa,"Fundación Santa Fe de Bogotá, Salud Poblacional, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Darío Londoño-Trujillo,"Fundación Santa Fe de Bogotá, Salud Poblacional, Colombia.",
39817585,Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.,2025,Sócrates Herrera-Valencia,"Centro Internacional de Vacunas, Cali, Colombia.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Júlia Corominas,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Carme Garriga,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Antoni Prenafeta,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Alexandra Moros,"HIPRA, Girona, Spain. Electronic address: sandra.moros@hipra.com.",sandra.moros@hipra.com
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Manuel Cañete,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Antonio Barreiro,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Luis González-González,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Laia Madrenas,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Irina Güell,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Montserrat Plana,"CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; AIDS Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Ignasi Esteban,"AIDS Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Elena Aurrecoechea,"AIDS Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Rachel Abu Taleb,"Veristat, LLC. Barcelona, Spain, Toronto, Canada, Pickmere, UK.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Paula McSkimming,"AIDS Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Eunate Arana-Arri,"Scientific Coordination, Biocruces Bizkaia HRI, Osakidetza, Barakaldo, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Susana Meijide,"Scientific Coordination, Biocruces Bizkaia HRI, Osakidetza, Barakaldo, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Natale Imaz-Ayo,"Scientific Coordination, Biocruces Bizkaia HRI, Osakidetza, Barakaldo, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Teresa Prat,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Èlia Torroella,"HIPRA, Girona, Spain.",
39809095,Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.,2025,Laura Ferrer,"HIPRA, Girona, Spain.",
39791506,Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study.,2025,Samuel Katsuyuki Shinjo,"Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.",
39791506,Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study.,2025,Francis Gullemin,"EA 4360 Apemac, Université de Lorraine, Nancy, France.",
39774938,Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.,2024,Clifton Kelly,"Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA.",
39774938,Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.,2024,So Hee Kim,"Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA.",
39774938,Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.,2024,Joy Miedema,"FHI 360, Durham, NC.",
39772248,Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients.,2024,Marc Lütgehetmann,"German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 38124 Braunschweig, Germany.",
